A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RG1662 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Caba, Argentina, C1428AQK
- Fleni
-
Ciudad Autonoma de Bs As, Argentina, 1426
- Instituto Neurologia Bs As
-
-
-
-
Nova Scotia
-
Kentville, Nova Scotia, Canada, B4N 4K9
- True North Clinical Research Kentville
-
-
-
-
-
Bron, France, 69003
- Groupement Hospitalier Est-Hopital Femme Mere enfant/Hospice civils de lyon
-
Montpellier, France, 34295
- CHU de Montpellier Hopital Arnaud de Villeneuve; de Génétique
-
Paris, France, 75015
- Institut Jérôme Lejeune; Neuropsychology
-
St Etienne, France, 42055
- CHU de Saint Etienne; Service de Génétique
-
-
-
-
Lazio
-
Roma, Lazio, Italy, 00165
- Ospedale Pediatrico Bambino Gesu
-
Roma, Lazio, Italy, 00168
- Policlinico Universitario "Agostino Gemelli";Dip. Tutela Salute Donna Bambino Adolescente
-
-
Sardegna
-
Cagliari, Sardegna, Italy, 09121
- Ospedale Microcitemico; Clinica Pediatrica
-
-
-
-
-
Aguascalientes, Mexico, 20030
- Clínica Para la Atención del Neurodesarrollo
-
Monterrey, Mexico, 64460
- Hospital Universitario Dr. Jose Eleuterio Gonzalez; Pediatria
-
Queretaro, Mexico, 76000
- Hospital Médica Tec 100
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 45200
- Hospital Dr. Angel Leaño; Pediatria
-
-
-
-
-
Auckland, New Zealand, 1142
- Auckland Clinical Studies
-
Dunedin, New Zealand, 9016
- University of Otago; Psychological Medicine Department
-
Wellington, New Zealand, 6021
- Wellington Hospital Research Office
-
-
-
-
-
Singapore, Singapore, 229899
- KK Women's and Children's Hospital; Department of Neonatology
-
-
-
-
-
Barcelona, Spain, 08009
- IMIM, Human Pharmacology and Clinical Neurosciences,
-
Madrid, Spain, 28009
- Hospital Infantil Universitario Niño Jesus; Pediatria Social
-
Madrid, Spain, 28006
- Hospital Universitario de la Princesa; Medicina Interna
-
Madrid, Spain, 28016
- Fundación Síndrome de Down; Fundación Síndrome de Down
-
-
Girona
-
Salt, Girona, Spain, 17090
- UVaMID Hospital Santa Caterina;; Servicio de Neurología
-
-
La Coruña
-
Santiago de Compostela, La Coruña, Spain, 15706
- Complejo Hospitalario Universitario de Santiago (CHUS); Area Asistencial Integrada de Pediatría
-
-
-
-
-
Blackpool, United Kingdom
- Blackpool Teaching Hospitals NHS Foundation Trust; Child Development and Family Support Centre
-
Dartford, Kent, United Kingdom, DA2 6PB
- Mental Health of Learning Disability, Kent & Medway NHS and Social Care Partnership Trust
-
Doncaster, United Kingdom, DN2 5LT
- Doncaster and Bassetlaw Hospitals NHS Foundation Trust; Doncaster Royal Infirmary
-
Redruth, United Kingdom, TR15 2SP
- Cornwall Partnership NHS Foundation Trust
-
-
-
-
California
-
La Jolla, California, United States, 92037
- Univ of CA San Diego; Neurosciences Comp.Alzheimer's
-
Sacramento, California, United States, 95817
- University of California DAVIS Medical Center; M.I.N.D. Institute, Section of Developmental Behavior
-
-
Georgia
-
Decatur, Georgia, United States, 30033
- Emory University School of Medicine; Department of Human Genetics & Pediatrics
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Hospital.
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusette General Hospital; Medical Genetics
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Clin Rsch Institute
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- University of Utah School of Medicine; Department of Pediatrics
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53705
- University of Wisconsin Madison, Waisman Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Individuals aged 12-30 years of age inclusive
- Clinical diagnosis of Down syndrome (trisomy 21) confirmed by chromosomal analysis (karyotyping)
- Males, or non-pregnant, non-lactating females. For females of childbearing potential, strict contraceptive prevention is required.
- Body-mass Index (BMI) 18-42 and 15-30 kg/m2 inclusive for adults and adolescents respectively
- Ability to complete the Clinical Evaluation of Language Fundamentals (CELF)-preschool 2 word classes task
- Subjects must have a parent, or other reliable caregiver who agrees to accompany the subject to all clinic visits, provide information about the subject as required by the protocol, and ensure compliance with the medication schedule
- Study participants must have sufficient language, vision and hearing to participate in study evaluations, as judged clinically by investigator
Exclusion Criteria:
- Subjects with a current DSM 5 diagnosis of any primary psychiatric diagnosis (including ASD or MDD)
- Subjects with a history of infantile spasms, of West syndrome, Lennox-Gastaut syndrome, Early Infantile Epileptic Encephalopathy or any treatment-refractory epilepsy associated with cognitive or developmental regression, of severe head trauma or CNS infections (e.g. meningitis)
- Subjects with a known or suspected clinical seizure event of any type within 24 months prior to screening
- Clinically relevant ECG abnormalities at screening or baseline; QTcF above 450 ms; personal or family history (first degree relatives) of congenital long QT syndrome
- Inadequate renal or hepatic function
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Placebo
|
Orally twice daily, 26 weeks
|
|
EXPERIMENTAL: RG1662 120 mg bid
|
120 mg (80 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
240 mg (160 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
|
|
EXPERIMENTAL: RG1662 240 mg bid
|
120 mg (80 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
240 mg (160 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cognition as assessed by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) sub-tests
Time Frame: 26 weeks
|
26 weeks
|
|
Adaptive behavior as assessed by the Vineland Adaptive Behavior Scales-II (VABS-II) standard scores
Time Frame: 26 weeks
|
26 weeks
|
|
Clinical global impression as assessed by Clinician Rated Global Improvement (CGI-I) scale
Time Frame: 26 weeks
|
26 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of abnormal ECG changes
Time Frame: 26 weeks
|
26 weeks
|
|
Abnormal ECG changes in adolescents as compared to baseline
Time Frame: from baseline to Week 26
|
from baseline to Week 26
|
|
Safety: Incidence of adverse events
Time Frame: approximately 32 weeks
|
approximately 32 weeks
|
|
Incidence of abnormal blood pressure
Time Frame: 26 weeks
|
26 weeks
|
|
RG1662 plasma concentrations
Time Frame: 26 weeks
|
26 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BP27832
- 2013-001263-23 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.